BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32886262)

  • 1. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
    Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
    Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
    Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
    Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
    Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
    J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.
    Nishimura MI; Kawakami Y; Charmley P; O'Neil B; Shilyansky J; Yannelli JR; Rosenberg SA; Hood L
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):85-94. PubMed ID: 7804531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
    Br J Cancer; 2024 May; ():. PubMed ID: 38750113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
    Zeppellini A; Galimberti S; Leone BE; Pacifico C; Riva F; Cicchiello F; Capici S; Maggioni C; Sala L; Cazzaniga ME
    BMC Cancer; 2021 Mar; 21(1):260. PubMed ID: 33691674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the T-cell receptor beta chain repertoire in tumor-infiltrating lymphocytes.
    Nakanishi K; Kukita Y; Segawa H; Inoue N; Ohue M; Kato K
    Cancer Med; 2016 Sep; 5(9):2513-21. PubMed ID: 27465739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor α and β Repertoires.
    Gil A; Kamga L; Chirravuri-Venkata R; Aslan N; Clark F; Ghersi D; Luzuriaga K; Selin LK
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas.
    Zhang Q; Jia Q; Deng T; Song B; Li L
    Biochem Biophys Res Commun; 2015 Feb; 458(1):70-6. PubMed ID: 25637538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response.
    Aran A; Lázaro G; Marco V; Molina E; Abancó F; Peg V; Gión M; Garrigós L; Pérez-García J; Cortés J; Martí M
    Front Immunol; 2023; 14():1227766. PubMed ID: 37600765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAV gene expression in PBMCs and TILs in patients with breast cancer analyzed by a DNA melting curve (FQ-PCR) technique for TCR α chain CDR3 spectratyping.
    He XY; Yang WM; Tang WT; Ma R; Sun YP; Wang P; Yao XS
    Neoplasma; 2012; 59(6):693-9. PubMed ID: 22862170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
    Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
    Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models.
    Morello G; Cancila V; La Rosa M; Germano G; Lecis D; Amodio V; Zanardi F; Iannelli F; Greco D; La Paglia L; Fiannaca A; Urso AM; Graziano G; Ferrari F; Pupa SM; Sangaletti S; Chiodoni C; Pruneri G; Bardelli A; Colombo MP; Tripodo C
    Cancer Immunol Res; 2021 Jul; 9(7):825-837. PubMed ID: 33941587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
    Page DB; Yuan J; Redmond D; Wen YH; Durack JC; Emerson R; Solomon S; Dong Z; Wong P; Comstock C; Diab A; Sung J; Maybody M; Morris E; Brogi E; Morrow M; Sacchini V; Elemento O; Robins H; Patil S; Allison JP; Wolchok JD; Hudis C; Norton L; McArthur HL
    Cancer Immunol Res; 2016 Oct; 4(10):835-844. PubMed ID: 27587469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.